Bausch Health Cos Inc. (NYSE:BHC) Given Consensus Rating of “Reduce” by Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC) have been assigned a consensus recommendation of “Reduce” from the five research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a hold rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $8.3333.

A number of equities analysts have recently commented on the stock. Barclays cut their target price on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Weiss Ratings lowered shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Finally, Truist Financial lifted their price target on shares of Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a report on Wednesday, January 7th.

Institutional Trading of Bausch Health Cos

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ritholtz Wealth Management boosted its holdings in Bausch Health Cos by 178.8% during the first quarter. Ritholtz Wealth Management now owns 222,459 shares of the company’s stock worth $1,201,000 after buying an additional 142,663 shares in the last quarter. Viewpoint Capital Management LLC purchased a new stake in shares of Bausch Health Cos in the first quarter worth approximately $97,000. Caitong International Asset Management Co. Ltd grew its position in Bausch Health Cos by 25,689.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 10,058 shares of the company’s stock valued at $70,000 after purchasing an additional 10,019 shares in the last quarter. Aristides Capital LLC purchased a new stake in Bausch Health Cos in the 4th quarter worth approximately $199,000. Finally, Invesco Ltd. grew its holdings in shares of Bausch Health Cos by 5.9% during the 4th quarter. Invesco Ltd. now owns 178,607 shares of the company’s stock valued at $1,241,000 after acquiring an additional 9,940 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors.

Bausch Health Cos Stock Performance

NYSE:BHC opened at $5.85 on Tuesday. Bausch Health Cos has a twelve month low of $4.41 and a twelve month high of $8.69. The company has a market capitalization of $2.19 billion, a P/E ratio of 14.01 and a beta of 0.40. The firm has a 50-day moving average price of $5.56 and a two-hundred day moving average price of $6.23. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, February 18th. The company reported $1.08 EPS for the quarter, missing the consensus estimate of $1.21 by ($0.13). The business had revenue of $2.78 billion during the quarter, compared to analyst estimates of $2.71 billion. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. As a group, research analysts expect that Bausch Health Cos will post 4.15 earnings per share for the current fiscal year.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.